Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gilead Sciences is conducting a Phase 3 study titled ‘A Phase 3 Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in Subjects With Hormonal Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens.’ The study aims to evaluate the effectiveness of sacituzumab govitecan-hziy compared to standard treatments chosen by physicians for patients with HR+/HER2- metastatic breast cancer who have not responded to at least two previous chemotherapy treatments.
The intervention being tested is sacituzumab govitecan-hziy, an experimental drug administered intravenously. It is designed to treat HR+/HER2- metastatic breast cancer, offering a potential new option for patients who have exhausted other chemotherapy options.
This interventional study is randomized with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on comparing the new drug against existing treatment options.
The study began on November 23, 2020, with an active, not recruiting status as of the last update on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could impact treatment protocols.
The outcome of this study could significantly influence Gilead Sciences’ stock performance, as positive results may enhance the company’s market position in the oncology sector. Investors should watch for updates, as successful trials could shift market dynamics, especially in comparison to competitors in the breast cancer treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.